Sponsor Name: Eli Lilly and Company
Protocol Title: A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease
Participants at Risk for Cognitive and Functional Decline
Regulatory Agency Identifier Numbers: IND: 137063; EU trial number: 2024-515656-20-00
Rationale: The pathophysiological process of Alzheimer’s disease (AD) begins more than a
decade before the clinical stage now recognized as AD dementia. Compounds targeting the
underlying disease process may have greater benefit when started earlier in the disease
continuum.
This Phase 3 study will evaluate the safety and efficacy of remternetug in participants who have
early AD. The primary objective of Study J1G-MC-LAKI (LAKI) will assess whether treatment
with remternetug delays the time to clinically meaningful progression as compared to placebo.